Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Operating profit has grown by an annual rate 0.83% of over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
Poor long term growth as Operating profit has grown by an annual rate 0.83% of over the last 5 years
3
Flat results in Apr 25
4
With ROE of 15.12%, it has a expensive valuation with a 2.02 Price to Book Value
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
SEK 16,933 Million (Small Cap)
13.00
NA
10.45%
0.45
15.12%
1.86
Revenue and Profits:
Net Sales:
3,646 Million
(Quarterly Results - Jul 2025)
Net Profit:
106 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
23.84%
0%
23.84%
6 Months
13.06%
0%
13.06%
1 Year
-9.19%
0%
-9.19%
2 Years
-31.96%
0%
-31.96%
3 Years
-9.74%
0%
-9.74%
4 Years
-47.16%
0%
-47.16%
5 Years
-49.25%
0%
-49.25%
Elekta AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.44%
EBIT Growth (5y)
0.83%
EBIT to Interest (avg)
7.67
Debt to EBITDA (avg)
0.93
Net Debt to Equity (avg)
0.41
Sales to Capital Employed (avg)
1.07
Tax Ratio
51.02%
Dividend Payout Ratio
386.91%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
17.18%
ROE (avg)
13.38%
Valuation key factors
Factor
Value
P/E Ratio
13
Industry P/E
Price to Book Value
2.02
EV to EBIT
10.41
EV to EBITDA
8.12
EV to Capital Employed
1.71
EV to Sales
1.26
PEG Ratio
1.17
Dividend Yield
9.64%
ROCE (Latest)
16.38%
ROE (Latest)
15.12%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
No Trend
Shareholding Snapshot : Oct 2022
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jul'25 - YoY
Jul'25
Jul'24
Change(%)
Net Sales
3,646.00
3,825.00
-4.68%
Operating Profit (PBDIT) excl Other Income
363.00
413.00
-12.11%
Interest
83.00
83.00
Exceptional Items
-16.00
-78.00
79.49%
Consolidate Net Profit
106.00
71.00
49.30%
Operating Profit Margin (Excl OI)
60.90%
66.70%
-0.58%
USD in Million.
Net Sales
YoY Growth in quarter ended Jul 2025 is -4.68% vs -0.08% in Jul 2024
Consolidated Net Profit
YoY Growth in quarter ended Jul 2025 is 49.30% vs -70.17% in Jul 2024
Annual Results Snapshot (Consolidated) - Apr'25
Apr'25
Apr'24
Change(%)
Net Sales
18,016.00
18,119.00
-0.57%
Operating Profit (PBDIT) excl Other Income
3,514.00
3,498.00
0.46%
Interest
471.00
482.00
-2.28%
Exceptional Items
-1,207.00
0.00
Consolidate Net Profit
241.00
1,302.00
-81.49%
Operating Profit Margin (Excl OI)
122.90%
130.40%
-0.75%
USD in Million.
Net Sales
YoY Growth in year ended Apr 2025 is -0.57% vs 7.41% in Apr 2024
Consolidated Net Profit
YoY Growth in year ended Apr 2025 is -81.49% vs 37.92% in Apr 2024
About Elekta AB 
Elekta AB
Pharmaceuticals & Biotechnology
Elekta publ AB is a Sweden-based human care company that develops and sells clinical solutions for the treatment of cancer and brain disorder. The Company offers and develops systems for radiation therapy and radio-surgery, as well as software systems that enhance workflow efficiency throughout the entire spectrum of cancer care. The Company has four product areas: Elekta Neuroscience, which develops solutions for the diagnosis and treatment of neurological diseases; Elekta Oncology, which creates clinical solutions for radiation therapy, such as linear accelerators, integrated imaging systems and clinical solutions for patient positioning and immobilization; Elekta Brachytherapy, which is engaged in the treatment of cancer through internal radiation, and Elekta Software, which develops software solutions for patient information, workflow management and treatment planning in oncology. The Company owns the service business of Asesores Electronicos Especializados SA de CV (AEESA).
Company Coordinates 
Company Details
Kungstensgatan 18, Box 7593 , STOCKHOLM None : 103 93
Registrar Details






